SCHEMBL7073069

SCHEMBL7073069

OCCCc1nc2cncnc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.46
PKM P14618 3/20 0.39
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.34
MAPT P10636 3/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
EGFR P00533 4/20 0.32
MAPK14 Q16539 1/20 0.32
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6948809 0.90 RAD52 (0.35) RAD52KDM4E
SCHEMBL7851162 0.84 PARP1 (0.43) ALDH1A1
SCHEMBL4957388 0.83 KDM4E (0.38) KMT2AKDM4EMEN1TDP1EGFR
SCHEMBL4962380 0.83 PI4KA (0.48) POLB
SCHEMBL9598378 0.80 KDM4C (0.35) KDM4E
SCHEMBL4955468 0.80 KDM4C (0.32)
SCHEMBL9572852 0.76 EGFR (0.31) EGFR
SCHEMBL5062600 0.76 DDAH1 (0.42) EGFR
SCHEMBL4957459 0.76 EGFR (0.31) EGFR
SCHEMBL6946791 0.75 RAB9A (0.54) ALDH1A1MAPTKMT2AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4925901-A STORAGE STAABILITY, ONIUM ION CATALYST THE DOW CHEMICAL COMPANY (US) 1990-05-15 US claimed
EP-3265447-B1 BENZOXAZINE LOW TEMPERATURE CURABLE COMPOSITION HUNTSMAN ADVANCED MAT AMERICAS LLC (US) 2023-03-01 EP disclosed
US-20180030264-A1 Benzoxazine Low Temperature Curable Composition HUNTSMAN ADVANCED MATERIALS AMERICAS LLC 2018-02-01 US disclosed
EP-3265447-A1 BENZOXAZINE LOW TEMPERATURE CURABLE COMPOSITION Huntsman Advanced Materials Americas LLC (US) 2018-01-10 EP disclosed
EP-0458502-B1 Latent catalysts, cure-inhibited epoxy resin compositions and laminates prepared therefrom DOW GLOBAL TECHNOLOGIES INC (US) 2003-06-18 EP disclosed
EP-0328020-B1 Use of a catalyst in epoxy compositions DOW CHEMICAL CO (US) 1996-10-09 EP disclosed
US-5503937-A MIXTURE OF A COMPOUND HAVING MORE THAN ONE EPOXY GROUP, A DIHYDRIC PHENOLIC COMPOUND AND A LATENT CATALYST COMPRISING A SALT OF AN N-HETEROCYCLIC COMPOUND AND AN ACID HAVING A STRONG NUCLEOPHILIC ANION; COATINGS/MOLDINGS; STORAGE THE DOW CHEMICAL COMPANY (US) 1996-04-02 US disclosed
EP-0553887-A2 Catalysts and epoxy resin composition containing the same THE DOW CHEMICAL COMPANY (US) 1993-08-04 EP disclosed
US-5169473-A Complex of an onium, arsenic or amine compound and boric acid; advanced polyepoxides; storage stability THE DOW CHEMICAL COMPANY (US) 1992-12-08 US disclosed
US-5134239-A Quaterinary indolizine compound THE DOW CHEMICAL COMPANY (US) 1992-07-28 US disclosed
EP-0458502-A2 Latent catalysts, cure-inhibited epoxy resin compositions and laminates prepared therefrom THE DOW CHEMICAL COMPANY (US) 1991-11-27 EP disclosed
US-4925901-A STORAGE STAABILITY, ONIUM ION CATALYST THE DOW CHEMICAL COMPANY (US) 1990-05-15 US disclosed
EP-0328020-A2 Use of a catalyst in epoxy compositions THE DOW CHEMICAL COMPANY (US) 1989-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030264-A1 Benzoxazine Low Temperature Curable Composition CRYZ, PIEZO1, PSMD12 RAD52 545/4885PKM 3416/4885ALDH1A1 1543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.